MARKET

GRI

GRI

GRI Bio
NASDAQ
1.510
+0.070
+4.86%
After Hours: 1.530 +0.02 +1.32% 19:59 04/04 EDT
OPEN
1.350
PREV CLOSE
1.440
HIGH
1.700
LOW
1.210
VOLUME
866.84K
TURNOVER
--
52 WEEK HIGH
172.49
52 WEEK LOW
1.210
MARKET CAP
793.29K
P/E (TTM)
-0.0274
1D
5D
1M
3M
1Y
5Y
1D
GRI BIO ANNOUNCES CLOSING OF $5.0 MILLION PUBLIC OFFERING
Reuters · 4d ago
GRI Stock Down on Public Offering Despite Encouraging IPF Study Data
Barchart · 4d ago
GRI Bio Shares Jump After Drug-Trial Update, Hit 52-Week Low After Offering News
Dow Jones · 5d ago
GRI BIO ANNOUNCES PRICING OF $5.0 MILLION PUBLIC OFFERING
Reuters · 5d ago
Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?
Benzinga · 5d ago
GRI Bio reports interim 2-week safety results from Phase 2a study of GRI-0621
TipRanks · 5d ago
GRI Bio Reported Interim 2-Week Safety Results From Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis
Benzinga · 5d ago
GRI BIO INC - INTERIM BIOMARKER DATA EXPECTED Q2 2025, TOPLINE RESULTS Q3 2025
Reuters · 5d ago
More
About GRI
More
GRI Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Its therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as an oral therapeutic for the treatment of idiopathic pulmonary fibrosis (IPF). Its product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. The Company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) or lupus and multiple sclerosis (MS).
Recently
Symbol
Price
%Change

Webull offers GRI Bio Inc stock information, including NASDAQ: GRI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GRI stock methods without spending real money on the virtual paper trading platform.